Operating at the forefront of innovation within Munich’s biotech hub, we use cutting-edge mass spectrometry technologies to screen libraries of tens of thousands of compounds against proteomes of more than 10,000 proteins. Our integrated target discovery engine accesses this unprecedented molecular landscape to connect innovative degrader chemistries with the previously undruggable proteome. Systematically extracted neosubstrate candidates are then validated as degrader targets by, for example, ubiquitination analysis to an unparalleled depth of 50,000 sites. Every connection is a new entry point for drug discovery, feeding broad pipelines of first-in-class therapeutics against novel, high-value targets.
